In the experimental phase, nuclear receptor agonists, such as peroxisome proliferator-activated receptor gamma (PPARγ) and liver X receptor (LXR), have shown efficacy by inhibiting Th17 differentiation and attenuating pathology in PD models. The gene discussed is PPARG; the disease is Parkinson disease.